Q&A: Demis Has­s­abis talks 'tur­bocharg­ing' Iso­mor­phic with $600M, ex­pand­ing in­to an­ti­bod­ies and the US

Iso­mor­phic Labs wants to achieve “max­i­mum ac­cel­er­a­tion” on its drug dis­cov­ery re­search progress, Demis Has­s­abis told End­points News.

In an in­ter­view on Mon­day short­ly af­ter …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER